EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (TKIs) are superior to chemotherapy in EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC) and are associated with a relatively rapid time to response [7,8].